118 related articles for article (PubMed ID: 10952123)
1. Innovative therapies for advanced ovarian cancer.
Trimble EL
Semin Oncol; 2000 Jun; 27(3 Suppl 7):24-30. PubMed ID: 10952123
[TBL] [Abstract][Full Text] [Related]
2. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
3. Achievements and unmet needs in the management of advanced ovarian cancer.
Guarneri V; Piacentini F; Barbieri E; Conte PF
Gynecol Oncol; 2010 May; 117(2):152-8. PubMed ID: 20056266
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of epithelial ovarian cancer].
Langmár Z; Csömör S
Orv Hetil; 2006 Aug; 147(34):1627-32. PubMed ID: 17017677
[TBL] [Abstract][Full Text] [Related]
5. Emerging drugs for ovarian cancer.
Kelland LR
Expert Opin Emerg Drugs; 2005 May; 10(2):413-24. PubMed ID: 15934876
[TBL] [Abstract][Full Text] [Related]
6. Role of pegylated liposomal doxorubicin in ovarian cancer.
Thigpen JT; Aghajanian CA; Alberts DS; Campos SM; Gordon AN; Markman M; McMeekin DS; Monk BJ; Rose PG
Gynecol Oncol; 2005 Jan; 96(1):10-8. PubMed ID: 15589573
[TBL] [Abstract][Full Text] [Related]
7. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.
Saucier JM; Yu J; Gaikwad A; Coleman RL; Wolf JK; Smith JA
J Oncol Pharm Pract; 2007 Mar; 13(1):39-45. PubMed ID: 17621566
[TBL] [Abstract][Full Text] [Related]
8. Advances in the management of epithelial ovarian cancer.
Berkenblit A; Cannistra SA
J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567
[TBL] [Abstract][Full Text] [Related]
9. Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature.
Grossi F; Aita M; Follador A; Defferrari C; Brianti A; Sinaccio G; Belvedere O
Oncologist; 2007 Apr; 12(4):451-64. PubMed ID: 17470688
[TBL] [Abstract][Full Text] [Related]
10. New, expanded, and modified use of approved antineoplastic agents in ovarian cancer.
Markman M
Oncologist; 2007 Feb; 12(2):186-90. PubMed ID: 17296814
[TBL] [Abstract][Full Text] [Related]
11. [Current trends in pharmacotherapy of breast cancer].
Boér K
Orv Hetil; 2002 Apr; 143(14):725-30. PubMed ID: 11975393
[TBL] [Abstract][Full Text] [Related]
12. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions.
Gasparini G; Longo R; Fanelli M; Teicher BA
J Clin Oncol; 2005 Feb; 23(6):1295-311. PubMed ID: 15718328
[TBL] [Abstract][Full Text] [Related]
13. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.
du Bois A; Weber B; Rochon J; Meier W; Goupil A; Olbricht S; Barats JC; Kuhn W; Orfeuvre H; Wagner U; Richter B; Lueck HJ; Pfisterer J; Costa S; Schroeder W; Kimmig R; Pujade-Lauraine E; ; ;
J Clin Oncol; 2006 Mar; 24(7):1127-35. PubMed ID: 16505432
[TBL] [Abstract][Full Text] [Related]
14. Ovarian cancer: a focus on management of recurrent disease.
Herzog TJ; Pothuri B
Nat Clin Pract Oncol; 2006 Nov; 3(11):604-11. PubMed ID: 17080178
[TBL] [Abstract][Full Text] [Related]
15. Novel therapies for recurrent ovarian cancer management.
Bhoola SM; Alvarez RD
Expert Rev Anticancer Ther; 2004 Jun; 4(3):437-48. PubMed ID: 15161442
[TBL] [Abstract][Full Text] [Related]
16. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
17. Pros and cons for systemic therapy in recurrent ovarian cancer.
Oskay-Ozcelik G; Sehouli J
Anticancer Res; 2009 Jul; 29(7):2831-6. PubMed ID: 19596970
[TBL] [Abstract][Full Text] [Related]
18. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
Garcia-Carbonero R; Supko JG
Clin Cancer Res; 2002 Mar; 8(3):641-61. PubMed ID: 11895891
[TBL] [Abstract][Full Text] [Related]
19. Improving the toxicity profile of chemotherapy for advanced ovarian cancer: a potential role for CT-2103.
Markman M
J Exp Ther Oncol; 2004 Jul; 4(2):131-6. PubMed ID: 15500007
[TBL] [Abstract][Full Text] [Related]
20. A review of systemic therapy for advanced pancreatic cancer.
El-Rayes BF; Philip PA
Clin Adv Hematol Oncol; 2003 Jul; 1(7):430-4. PubMed ID: 16258429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
